title: Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
abstract: To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrine-responsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high.
authors.affiliation: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland. olivia.pagani@ibcsg.org
authors.forename: Olivia
authors.initials: O
authors.lastname: Pagani
authors.forename: Shari
authors.initials: S
authors.lastname: Gelber
authors.forename: Edda
authors.initials: E
authors.lastname: Simoncini
authors.forename: Monica
authors.initials: M
authors.lastname: Castiglione-Gertsch
authors.forename: Karen N
authors.initials: KN
authors.lastname: Price
authors.forename: Richard D
authors.initials: RD
authors.lastname: Gelber
authors.forename: Stig B
authors.initials: SB
authors.lastname: Holmberg
authors.forename: Diana
authors.initials: D
authors.lastname: Crivellari
authors.forename: John
authors.initials: J
authors.lastname: Collins
authors.forename: Jurij
authors.initials: J
authors.lastname: Lindtner
authors.forename: Beat
authors.initials: B
authors.lastname: Thürlimann
authors.forename: Martin F
authors.initials: MF
authors.lastname: Fey
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Murray
authors.forename: John F
authors.initials: JF
authors.lastname: Forbes
authors.forename: Alan S
authors.initials: AS
authors.lastname: Coates
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004703:Endocrine System / Q000187:drug effects*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007390:International Agencies; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology*; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D017698:Postmenopause; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism*; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D011960:Receptors, Estrogen; D013629:Tamoxifen; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate